tiprankstipranks
VIRX Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsVIRX Upcoming Earnings Report: What to Expect?
22d ago
Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink
3M ago
Viracta Therapeutics price target lowered to $4 from $6 at RBC Capital
Premium
The Fly
Viracta Therapeutics price target lowered to $4 from $6 at RBC Capital
3M ago
Xoma receives $8.1M milestone related to Day One’s sale of PRV
PremiumThe FlyXoma receives $8.1M milestone related to Day One’s sale of PRV
6M ago
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
Premium
The Fly
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
6M ago
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
Premium
The Fly
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
6M ago
Viracta Therapeutics reports Q4 EPS (35c), consensus (31c)
PremiumThe FlyViracta Therapeutics reports Q4 EPS (35c), consensus (31c)
9M ago
Viracta announces completion of second-stage enrollment in NAVAL-1 trial
Premium
The Fly
Viracta announces completion of second-stage enrollment in NAVAL-1 trial
9M ago
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
Premium
The Fly
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100